ConfometRx, UCB deal

UCB and structural biology company ConfometRx partnered to research GPCR modulation to discover new therapies for neuroscience indications. UCB said the deal aims to obtain the crystal structures of GPCR targets bound to UCB molecules. The two-year deal includes an undisclosed upfront payment, research funding and milestones, but the partners did not disclose details. ...